gip glp 1 agonist tirzepatide Dual GLP-1/GIP | | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Bridging the gap between GLP1-receptor

Lancet 390(10103):16641675 Athauda D, Gulyani S, Kumar Karnati H et al (2019) Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial

Zhang, J., et al., Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management

There is also concern regarding the potential risk of non-arteritic anterior ischemic optic neuropathy, although the study in question had several limitations [15]

Tirzepatide is a dual-action medication that targets both GLP-1 and GIP receptors, which is why clinical trials have shown it producing greater average weight loss than semaglutide alone

There is no single best GLP-1 medication for weight loss because the right choice depends on your health history, your goals, your tolerance for a daily versus weekly routine, and what your clinician concludes after reviewing your full picture